mul osteti eelturult 7.32-ga. Järelikult kauplejatel mõtekas ebareaalseid ordereid tilbendada lasta. Nüüd sai 6.2-ga asemele osta.
fjotile: ega peagi tõhus olema, peab tõhusana näima.
heh,ma just vaatasin et kuidas see p2eva tipp t2na lausa 7.32 on.Tundus v2he uskumatu ,aga noh igasuguseid inimesi leidub.m2ned n2ed ostavad lausa sellise hinnaga.Ise soetasin pisut 6.14 pealt endalegi.
Tõhususest rääkides, ma ise ka mõtlesin, et ei tundu eriti toimiv. Aga kui ma ei eksi, siis kllinilisi katseid tehakse meeste peal, kelle puhul muu ravi tulutu on, haigus liiga kaugele arenenud jne. Ehk siis reaaelus on tulemused palju paremad.
DNDN rallib alla.
...näib nagu oleks DNDN kuulsusetu lõpp saabumas....kõik soovivad müüa
hea võimalus osta. max kuu aja jooksul saab siis jälle min 6.5-ga müüa.
Mmm. mina näen ostu kohta
täna müües saaksid nädala taksojuhi tiitli:)
kas keegi saab aru ka mis toimub või ... minu jaoks ei ole DNDN kunagi ühelegi loogikale vastanud.. ma ei tea miks ma seda nii väga hoian aga jätkan hoidmist :) õigemini loogika on... kui tuleb normaalne (võiks öelda kui mitte hea siis vähemalt neutraalne uudis) siis igaljuhul kõik müüvad... ilmselt ma lihtsalt ei saa asjast aru
hea näide selle kohta, miks stop-loss ordereid (alati) kasutada ei tasu.
Reedel tuleb välja kolmanda kvartali tulemustega, mis kajastab ilmselt suurt kahjumit ... ja kõik tõttavad ostma. Eks siin shortid mängivad oma rolli ja liikumised on tihtipeale loogikale vastupidised. Samas kardan seda, et ühtlasi võivad teatada aktsiakapitali laiendamisest, millest räägiti augusti keskpaigas. Sellisel juhul arvan, et liikumine tuleb esialgselt siiski järsult veel allapoole. Eks siis tuleb passida, millal shortid katma hakkavad.
.. no jah eks siin ilmselt mingi seletus ikka on jah.. :)) aga samas tundub ikka imelik, et kas on tõesti mõni ".....", kes arvab, et ei tule kahjum, et on hoopis järsku kasum vms.. ma imestan et see ei ole hinna sees juba ammu veel enam, et nüüd järsku 10% alla ?!?!... aga OK ... võibolla see a kapitali laiendamine pole jah kuigi hea uudis, mida võiks karta.. samas raha tuleb aktsiate eest ju ühingusse sisse.. on seal siis nii suurt vahet... aga ok ma ei piina seda foorumit oma (mitte väga viljakate) mõtetega :))) ... vahest lihtsalt vajad toru kuhu kisada kui asjade käigust aru ei saa ;)
09:30 DNDN Dendreon Announces FDA Grants Fast Track Status for PROVENGE (5.90 +0.30)
kas aktsias lühikesed hakkavad katma, loogiline oleks......
15 miljonit aktsiat on lühikeseks müüdud, positsioonide katmise korral võiks aktsia visata mõne nädalaga 8-9 $-ni, siis jaanuaris läheb avaldus sisse FDA-le jällegi tõus kuni 2$ ja kevadeks kauplemegi juba 10-12$ piirimail. See on positiivne stsenaarium.
...kõik turuosalised ootavad uudist võimalikest koostööpartneritest, kui midagi sellist maha öeldaks oleks võimas rakett see aktsia
Milleks kiirustada - vähemalt Traderitel peaks närvid olema veel "külmutatud" :))
Tra, mõelge kui LHV meeskond selle press-reliisi oleks ennem kätte saanud :)
target 19 USD, pole paha!
RY: Soleil: DNDN: Third Quarter Results & Dendreon's March toward Commercialization [FQBGDQV]
11:27am EDT 22-Nov-05 Soleil Securities Group Inc. (Jenny Freeman) DNDN NUVO
Cheirologic Partners, Inc. Soleil Securities Group
Equity Research November 22, 2005
Company Update Sales and Trading
Earnings Release 1-800-569-2407
http://www.soleilgroup.com
Jenny E. Freeman, MD
781-760-5569, jfreeman@unconventional-inc.com
Third Quarter Results & Dendreon's March toward Commercialization
Dendreon DNDN,$6.00, Buy
ACTION
Dendreon (DNDN) announced its financial results for 3Q 2005 November 4, 2005,
with a press release and associated conference call. Dendreon reported a loss
($0.33) per share, $0.01 higher than our and Wall Street consensus estimates
of ($0.34). The company's main highlight for the quarter included the decision
to submit a BLA for Provenge to the FDA based upon its Phase III 9901 and
9902A studies in men with androgen independent prostate cancer. Subsequent
approval for FDA Fast Track status on November 4 confirmed the company's
serious march toward commercialization. In the quarter, the company also
presented final 9902A data, supporting the 9901 survival data, at the ECCO 13
conference in Paris. These events support our thesis and financial models as
previously derived. Based on our 40X multiple of 2008 EPS of $1.59 discounted
back at 35%, we reach our price target of $19.
RY: Soleil: DNDN: Third Quarter Results & Dendreon's March toward Commercialization [FQBGDQV]
11:27am EDT 22-Nov-05 Soleil Securities Group Inc. (Jenny Freeman) DNDN NUVO
Cheirologic Partners, Inc. Soleil Securities Group
Equity Research November 22, 2005
Company Update Sales and Trading
Earnings Release 1-800-569-2407
http://www.soleilgroup.com
Jenny E. Freeman, MD
781-760-5569, jfreeman@unconventional-inc.com
Third Quarter Results & Dendreon's March toward Commercialization
Dendreon DNDN,$6.00, Buy
ACTION
Dendreon (DNDN) announced its financial results for 3Q 2005 November 4, 2005,
with a press release and associated conference call. Dendreon reported a loss
($0.33) per share, $0.01 higher than our and Wall Street consensus estimates
of ($0.34). The company's main highlight for the quarter included the decision
to submit a BLA for Provenge to the FDA based upon its Phase III 9901 and
9902A studies in men with androgen independent prostate cancer. Subsequent
approval for FDA Fast Track status on November 4 confirmed the company's
serious march toward commercialization. In the quarter, the company also
presented final 9902A data, supporting the 9901 survival data, at the ECCO 13
conference in Paris. These events support our thesis and financial models as
previously derived. Based on our 40X multiple of 2008 EPS of $1.59 discounted
back at 35%, we reach our price target of $19.
Dendreon Announces Public Offering of Common Stock
SEATTLE, WA, November 28, 2005 - Dendreon Corporation (Nasdaq: DNDN) today announced that it plans to publicly offer 10,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The Company also intends to grant the underwriters of the offering an option to purchase up to an additional 1,500,000 shares of common stock. All of the shares will be sold by Dendreon. Banc of America Securities LLC will be the book-running manager for the offering. JMP Securities and Lazard Capital Markets will be co-managers.
A preliminary prospectus supplement relating to the offering of the securities will be filed with the Securities and Exchange Commission but remains subject to completion. These securities may not be sold nor may offers to buy the securities be accepted prior to the time that the prospectus supplement and related prospectus are delivered in final form. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the preliminary prospectus supplement relating to the offering may be obtained from Banc of America Securities LLC (by email at dg.prospectus_distribution@bofasecurities.com) or from Dendreon Corporation (Attn: Investor Relations, 3005 First Avenue, Seattle, WA 98121).
SEATTLE, WA, November 28, 2005 - Dendreon Corporation (Nasdaq: DNDN) today announced that it plans to publicly offer 10,000,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. The Company also intends to grant the underwriters of the offering an option to purchase up to an additional 1,500,000 shares of common stock. All of the shares will be sold by Dendreon. Banc of America Securities LLC will be the book-running manager for the offering. JMP Securities and Lazard Capital Markets will be co-managers.
A preliminary prospectus supplement relating to the offering of the securities will be filed with the Securities and Exchange Commission but remains subject to completion. These securities may not be sold nor may offers to buy the securities be accepted prior to the time that the prospectus supplement and related prospectus are delivered in final form. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. Copies of the preliminary prospectus supplement relating to the offering may be obtained from Banc of America Securities LLC (by email at dg.prospectus_distribution@bofasecurities.com) or from Dendreon Corporation (Attn: Investor Relations, 3005 First Avenue, Seattle, WA 98121).